➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Moodys
AstraZeneca
Merck
Johnson and Johnson

Last Updated: November 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Pirarubicin

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Pirarubicin?

Pirarubicin is an investigational drug.

There have been 21 clinical trials for Pirarubicin. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2019.

The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Transitional Cell, and Breast Neoplasms. The leading clinical trial sponsors are Beijing Jishuitan Hospital, Peking University First Hospital, and Peking University People's Hospital.

There is one US patent protecting this investigational drug and sixteen international patents.

Recent Clinical Trials for Pirarubicin
TitleSponsorPhase
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant ChemotherapyChinese Academy of Medical SciencesPhase 2
Combination Therapy of Anthracyclines for Children With NephroblastomaShengjing HospitalPhase 4
Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue SarcomaTianjin Medical University Cancer Institute and HospitalPhase 2

See all Pirarubicin clinical trials

Clinical Trial Summary for Pirarubicin

Top disease conditions for Pirarubicin
Top clinical trial sponsors for Pirarubicin

See all Pirarubicin clinical trials

US Patents for Pirarubicin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pirarubicin   Start Trial Heat shock protein 70 (hsp-70) receptor ligands Duke University (Durham, NC)   Start Trial
Pirarubicin   Start Trial Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus Seattle Genetics, Inc. (Bothell, WA)   Start Trial
Pirarubicin   Start Trial Bispecific antigen-binding constructs targeting HER2 Zymeworks Inc. (Vancouver, CA)   Start Trial
Pirarubicin   Start Trial Use of inhibitors of Bruton's tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Pirarubicin

Drugname Country Document Number Estimated Expiration Related US Patent
Pirarubicin World Intellectual Property Organization (WIPO) 2015148714 2034-03-25   Start Trial
Pirarubicin Australia 2006269422 2025-07-07   Start Trial
Pirarubicin Canada 2614436 2025-07-07   Start Trial
Pirarubicin European Patent Office 1917020 2025-07-07   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Moodys
AstraZeneca
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.